<DOC>
	<DOCNO>NCT02802657</DOCNO>
	<brief_summary>The study evaluate efficacy safety two different regimen Conbercept ( Treat-and-Extend Regimen vs. PRN ) patient wet AMD . This study provide long-term safety data treatment patient wet AMD .</brief_summary>
	<brief_title>A Study Comparing Efficacy Safety `` Treat-and-Extend '' Regimen Versus PRN Conbercept AMD</brief_title>
	<detailed_description>Inclusion Criteria： Age ≥ 50 y/o , nAMD patients（including PCV） Best-corrected visual acuity（BCVA） Exclusion Criteria： Previous anti-VEGF treatment within 3 month History intraocular surgery within 3 month arrangement intraocular surgery next 6 month baseline Active recent intraocular inflammation study eye Primary Endpoint： Improvement BCVA compare baseline Other： Central Macular Thickness Treatment，Numbers Injections</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Written informedconsent evaluation Visual impairment due active CNV , include predominantly classic CNV , minimally classic CNV , occult CNV classic component PCV . 50 year old old Chinese For study eye : BCVA 20/30 20/320 electronic visual acuity texting time point screen baseline . Have Stroke myocardial infarction within 3 month screen Any active periocular ocular infection inflammation ( include blepharitis , conjunctivitis , keratitis , scleritis , uveitis , intraocular inflammation ) screen baseline . Uncontrolled glaucoma ( treatment [ IOP ] ≥ 30 mm Hg depend researcher ) screen baseline Neovascularization iris neovascular glaucoma screen baseline Any cause lead choroidal neovascularization except Wet AMD ( include ICNV , central serous chorioretinopathy , ocular histoplazmoza pathologic myopia ) screen baseline With structure injury ( include vitreous macular traction , epiretinal membrane involve central fovea , subretinal fibroplasia , laser scar central fovea atrophy ) within 0.5 optic disc diameter central macula screen baseline , may harm improvement vision treatment accord researcher Any systemic antiVEGF medication ( Avastin ) use within 3 month screen Any medication systemic use toxic lens , retina optic nerve , include iron amine , chloroquine/chloroquine ( Plaquenil ® ) , tamoxifen , phenothiazine ethambutol For study eye：Used accept follow treatment wet AMD within 3 month accept follow treatment three time baseline : ) Antiangiogenesis drug ( pegaptanib （Macugen®），ranibizumab , bevacizumab（Avastin® ) , VEGFTrap，KH902；b）Anecortave acetate corticosteroids；c）Protein kinase C inhibitors，squalamine，siRNA ; ) PDT （Visudyne®）treatment , external beam radiotherapy , local laser photocoagulation , vitrectomy , submacular surgery transpupillary thermotherapy Any intraocular surgery ( include YAG laser ) within 3 month baseline predicate within 6 month baseline Intraocular periocular treatment corticosteroid within 3 month baseline For follow eye : Any antiangiogenesis treatment ( include antiVEGF , like Lucentis , Avastin® KH902 ) within 3 month baseline</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Age-related Macular Degeneration</keyword>
	<keyword>Conbercept</keyword>
	<keyword>Treat-and-Extend Regimen</keyword>
	<keyword>Pro Re Nata</keyword>
</DOC>